France's public health system will soon start to cover most of the cost of weight-loss drugs Wegovy and Mounjaro for severely obese patients.
The government has signed off on partially reimbursing patients who are prescribed Novo Nordisk's Wegovy and Eli Lilly's Mounjaro injectable GLP-1 medications, which have gained widespread attention as anti-obesity treatments.